Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major

Infection and Immunity

Volumn 72, Issue 10, 2004, Pages 5654-5661

  Tonui, Willy K ^a,b   Mejia, J Santiago ^a   Hochberg, Lisa ^d   Mbow, M Lamine ^a,e   Ryan, Jeffrey R ^d,f   Chan, Adeline S T ^d   Martin, Samuel K ^c   Titus, Richard G ^a  

^a Department of Ecosystem Science and Sustainability   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c U States Army Medical Research Unit   (Kenya)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e CENTOCOR INC   (United States)

^f CEPHEID   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CONCANAVALIN A; CYTOKINE; GLYCOPROTEIN; GLYCOPROTEIN GP 46; GLYCOPROTEIN GP 63; IMMUNOLOGICAL ADJUVANT; LEISHMANIA VACCINE; LIPOPHOSPHOGLYCAN; MEMBRANE ANTIGEN; MONTANIDE ISA 720; PARASITE ANTIGEN; RECOMBINANT INTERLEUKIN 12; REHYDRAGEL HPA; SOLUBLE EXOGENOUS ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNIZATION; IN VITRO STUDY; INGUINAL LYMPH NODE; LEISHMANIA MAJOR; LYMPHOID TISSUE; MONONUCLEAR CELL; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS; SPLEEN; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIGENS, PROTOZOAN; FEMALE; GLYCOSPHINGOLIPIDS; INTERLEUKIN-12; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TH1 CELLS; TH2 CELLS; VACCINATION;

EID: 4644242029     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.10.5654-5661.2004     Document Type: Article

References (31)

1. Afonso, L. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235-237.
2. Aucouturier J., L. Dupuis, S. Deville, S. Ascarateil, and V. Ganne. 2002. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1:111-118.
3. Baylor, N. W., W. Egan, and P. Richman. 2002. Aluminum salts in vaccines-US perspective, Vaccine 20:818-23.
4. Belkaid, Y., K. F. Hoffmann, S. Mendez, S. Kamhawi, M. C. Udey, T. A. Wynn, and D. L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194:1497-1506.
5. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502-507.
6. Brodskyn, C., de Oliviera, C., Barral, A., Barral-Netto, M. 2003. Vaccines in leishmaniasis: Advances in the last five years. Expert Rev. Vaccines 2:705-717.
7. Coler, R. N., Y. A. W. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, and S. G. Reed. 2002. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducibie protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:4215-4225.
8. Handman, E. 2001. Leishmaniasis: current status of vaccine development, Clin. Microbiol. Rev. 14:229-243.
9. Heinzel, F. P., M. D. Sadick, S. S. Mutha, and R. M. Locksley. 1991. Production of interferon-gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. USA 88:7011-7015.
10. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley. 1989. Reciprocal expression of interferon-gamma or interleukin-4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:59-72.
11. Hsieh, C. S., S. E. Macatonia, C. S. Tripp, S. F. Wolf, A. O'Garra, and K. M. Murphy. 1993. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547-549.
12. Jankovic, D., P. Caspar, M. Zweig, M. Garcia-Moll, S. D. Showalter, F. R. Vogel, and A. Sher. 1997. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1-cytokine responses to HIV-1 gp120. J. Immunol. 159:2409-2417.
13. Kennet, R. T., D. L. Sacks, J. P. Sypek, L. Vilela, A. A. Gam, and K. Evans-Davis. 1999. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163:4481-4488.
14. Lima, H. C., J. Bleyenberg, and R. G. Titus. 1997. A simple method for quantifying Leishmania in tissues of infected animals. Parasitol. Today 13:80-82.
15. Martin, S. K., L. Thuita-Harun, M. Adoyo-Adoyo, and K. M. Wasunna. 1998. A diagnostic ELISA for visceral leishmaniasis, based on antigen from media conditioned by Leishmania donovani promastigotes. Ann. Trop. Med. Parasitol. 92:571-577.
16. Maryanski, J., J. van Snick, J. C. Cerrotini, and T. Boon. 1982. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P 815.III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur. J. Immunol. 12:401-406.
17. Matthews, D. J., C. L. Emson, G. J. McKenzie, H. E. Jolin, J. M. Blackwell, and A. N. McKenzie. 2000. IL-13 is a susceptibility factor for Leishmania major infection. J. Immunol. 164:1458-1462.
18. Melby, P. C. 2002. Vaccination against cutaneous leishmaniasis. Current status. Am. J. Clin. Dermatol. 3:557-570.
19. Mendonca, S. C., P. M. De-Luca, R. W. Olafson, A. Jardim, and S. G. Coutinho. 1994. Does lipophosphoglycan enhance the T cell-stimulatory activity of lipophosphoglycan-associated proteins? Braz. J. Med. Biol. Res. 27:553-557.
20. Morris, S. C., K. B. Madden, J. J. Adamovicz, W. C. Gause, B. R. Hubbard, M. K. Gately, and F. D. Finkelman. 1994. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J. Immunol. 152:1047-1056.
21. Noben-Trauth, N., R. Lira, H. Nagase, W. E. Paul, and D. L. Sacks. 2003. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 170:5152-5158.
22. Noormohammadi, A. H., H. Hochrein, J. M. Curtis, T. M. Baldwin, and E. Handman. 2001. Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen. Vaccine 19:4043-4052.
23. Reed, S. G., and Campos-Neto, A. 2003. Vaccines for parasitic and bacterial diseases. Curr. Opin. Immunol. 15:456-460.
24. Reed, S. G., and P. Scott. 2000. Immunologic mechanisms in Leishmania, p. 537-554, In M. W. Cunningham and R. S. Fujinami (ed.), Effects of microbes on the immune system. Lippincott, Williams & Wilkins, Philadelphia, Pa.
25. Ryan, J. R., A M. Smithyman, G. H. Rajasekariah, L. Hochberg, J. M. Stiteler, and S. K. Martin. 2002. Enzyme-linked immunosorbent assay based on soluble promastigote antigen detects immunoglobulin M (IgM) and IgG antibodies in sera from cases of visceral and cutaneous leishmaniasis. J. Clin. Microbiol. 40:1037-1043.
26. Sacks, D. L., and P. V. Perkins. 1984, Identification of an infective stage of Leishmania promastigotes. Science 223:1417-1419.
27. Titus, R., F. Gueiros-Filho, L. A. de Freitas, and S. M. Beverley. 1995. Development of a safe live Leishmania vaccine line by gene replacement, Proc. Natl. Acad. Sci. USA 92:10267-10271.
28. Titus, R. G., C. M. Theodos, A. Shankar, and L. R. Hall. 1994. Interactions between Leishmania major and macrophages. Immunol. Ser. 60:437-459.
29. Trinchieri, G., M. Wysocka, A. D'Andrea, M. Rengaraju, M. Aste-Amezaga, M. Kubin, N. M. Valiante, and J. Chehimi. 1992. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog. Growth Factor Res. 4:355-368.
30. Webb, J. R., A. Campos-Neto, P. J. Ovendale, T. I. Martin, E. J. Stromberg, R. Badaro, and S. G. Reed. 1998. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66:3279-3289.
31. + T-cell activation-induced human immunodeficiency virus replication. Infect. Immun. 67:5258-5264.